Apatinib Combined With Temozolomide and Etoposide Capsules
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Medulloblastoma
Conditions
Recurrent Medulloblastoma
Trial Timeline
Oct 28, 2020 → Aug 31, 2025
NCT ID
NCT04501718About Apatinib Combined With Temozolomide and Etoposide Capsules
Apatinib Combined With Temozolomide and Etoposide Capsules is a phase 2 stage product being developed by Brain Biotech for Recurrent Medulloblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04501718. Target conditions include Recurrent Medulloblastoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04501718 | Phase 2 | Recruiting |
Competing Products
20 competing products in Recurrent Medulloblastoma